beta-escin and Phlebitis

Intravenous infusion of chemotherapy drugs can cause severe chemotherapy-induced phlebitis (CIP) in patients. However, the underlying mechanism of CIP development remains unclear.. RNA-sequencing analysis was used to identify potential disease targets in CIP. Guanylate binding protein-5 (GBP5) genetic deletion approaches also were used to investigate the role of GBP5 in NLR family pyrin domain containing 3 (NLRP3) inflammasome activation in lipopolysaccharide (LPS) primed murine bone-marrow-derived macrophages (BMDMs) induced by vinorelbine (VIN) in vitro and in mouse models of VIN-induced CIP in vivo. The anti-CIP effect of aescin was evaluated, both in vivo and in vivo.. Here, we show that the expression of GBP5 was upregulated in human peripheral blood mononuclear cells from CIP patients. Genetic ablation of GBP5 in murine macrophages significantly alleviated VIN-induced CIP in the experimental mouse model. Mechanistically, GBP5 contributed to the inflammatory responses through activating NLRP3 inflammasome and driving the production of the inflammatory cytokine IL-1β. Moreover, aescin, a mixture of triterpene saponins extracted from horse chestnut seed, can alleviate CIP by inhibiting the GBP5/NLRP3 axis.. These findings suggest that GBP5 is an important regulator of NLRP3 inflammasome in CIP mouse model. Our work further reveals that aescin may serve as a promising candidate in the clinical treatment of CIP.

Topics: Animals; Antineoplastic Agents; Escin; GTP-Binding Proteins; Humans; Inflammasomes; Interleukin-1beta; Leukocytes, Mononuclear; Lipopolysaccharides; Mice; NLR Family, Pyrin Domain-Containing 3 Protein; Phlebitis

Topics: Adult; Drug Evaluation; Escin; Female; Heparin; Humans; Leg; Male; Middle Aged; Phlebitis; Phosphatidylcholines; Rutin; Saponins; Thermography; Thrombosis; Varicose Veins; Vascular Diseases

Topics: Blood Circulation; Drug Combinations; Escin; Female; Humans; Phlebitis; Phosphatidylcholines; Rutin; Saponins; Varicose Veins

Controlled experiments confirmed the therapeutic usefulness in gynecology of a phlebokinetic drug, in which EPL (polyunsaturated phosphatidylcholine) was combined with escine and rutine. The drug is particularly recommended for the prophylaxis and treatment of vein disorders caused by oral contraceptives. A total of 75 patients were treated with the drug (Essaven), in addition to the usual treatment (such as anticoagulants), while 75 controls received the usual treatment only. Results were excellent in cases of varicose veins, where the symptoms were eliminated in almost all cases. In cases of phlebitis and thrombophlebitis, the response was less univocal, but a definite improvement was evident in a good number of cases treated with Essaven; the drug also favored the return to normal conditions after thrombophlebitis attacks, reducing the duration of their painful aftereffects. The drug can be used daily for very long periods without side effects. It can also be used safely during pregnancy, without adverse effects on the fetus and on delivery. It is regarded as ideal to avoid the side effects of contraceptives on the venous system.

Topics: Adult; Aged; Contraceptives, Oral; Escin; Female; Humans; Phlebitis; Phospholipids; Pregnancy; Rutin; Saponins; Varicose Veins

Topics: Aesculus; Anticoagulants; Drug Combinations; Escin; Humans; Phlebitis; Plant Extracts; Pregnancy; Pregnancy Complications; Thiamine; Thrombophlebitis